J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Book ChapterDOI
Mantle Cell Lymphoma
TL;DR: The mantle cell lymphoma (MCL) has been recognized as carrying both features of indolent lymphoma and a more aggressive course with short response to standard chemotherapy and common chemoresistance over time leading to very poor long-term prognosis as mentioned in this paper.
Journal ArticleDOI
Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT).
John Steuter,Mary Lee H. Villanueva,Fausto R. Loberiza,James O. Armitage,Robert G. Bociek,Apar Kishor Ganti,Stefano R. Tarantolo,Julie M. Vose,Arthur R. Easley,Philip J. Bierman +9 more
TL;DR: A retrospective study to determine the incidence of AF/AFL following auto-HSCT and the risk factors associated with the development of AF-AFL and found older age, odds ratio and 95% CI of 1.07–1.21 were risk factors.
Journal ArticleDOI
Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).
Bruce D. Cheson,Julie M. Vose,Nancy L. Bartlett,A. Lopez,R. H. Van der Jagt,Anthony W. Tolcher,Dennis D. Weisenburger,A. L. Seiz,S. Shamsili,Anne Keating +9 more
TL;DR: YM 155 is well tolerated and has modest single-agent, anti-tumor activity in relapsed/refractory DLBCL patients, and preliminary data showing synergism when YM155 is combined with other agents additional clinical studies are being planned.
Journal ArticleDOI
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement : An international multicenter collaboration
Chan Yoon Cheah,Chan Yoon Cheah,Paul J. Bröckelmann,Paul J. Bröckelmann,Dai Chihara,Alison J. Moskowitz,Andreas Engert,Mats Jerkeman,Tarec Christoffer El-Galaly,Bradley Augustson,Julie M. Vose,Nancy L. Bartlett,Diego Villa,Joseph M. Connors,Tatyana Feldman,Chelsea C. Pinnix,Sarah A. Milgrom,Bouthaina S. Dabaja,Yasuhiro Oki,Michelle A. Fanale +19 more
TL;DR: CNS involvement as a feature of relapsed/refractory disease was adversely prognostic for both PFS and OS; however, four patients remain alive and free of relapse at 7–78 months follow‐up.